BidaskClub cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a sell rating in a research note released on Tuesday morning, BidAskClub reports.

Several other analysts have also weighed in on the stock. Barrington Research reiterated a buy rating and set a $38.00 target price on shares of LeMaitre Vascular in a research report on Friday, February 7th. ValuEngine lowered shares of LeMaitre Vascular from a hold rating to a sell rating in a research report on Friday, February 7th. Lake Street Capital upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $40.00 target price on the stock in a research report on Thursday, October 24th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $33.00 target price on the stock in a research report on Tuesday. Finally, First Analysis lowered shares of LeMaitre Vascular from a strong-buy rating to an outperform rating and lifted their target price for the company from $37.00 to $40.00 in a research report on Thursday, October 24th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. LeMaitre Vascular has a consensus rating of Hold and a consensus price target of $37.75.

NASDAQ LMAT traded up $0.27 during midday trading on Tuesday, hitting $30.11. The company had a trading volume of 75,439 shares, compared to its average volume of 139,486. The stock has a market cap of $569.65 million, a price-to-earnings ratio of 34.22, a P/E/G ratio of 3.63 and a beta of 1.23. The firm has a fifty day simple moving average of $35.56 and a two-hundred day simple moving average of $34.15. LeMaitre Vascular has a fifty-two week low of $24.71 and a fifty-two week high of $38.64.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.23. The company had revenue of $30.20 million for the quarter, compared to analyst estimates of $30.44 million. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the business posted $0.30 EPS. As a group, research analysts anticipate that LeMaitre Vascular will post 0.94 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, March 3rd will be given a dividend of $0.095 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.09. This represents a $0.38 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Monday, March 2nd. LeMaitre Vascular’s payout ratio is 38.64%.

In other LeMaitre Vascular news, CFO Joseph P. Pellegrino, Jr. sold 710 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $36.07, for a total value of $25,609.70. Following the transaction, the chief financial officer now directly owns 11,021 shares in the company, valued at $397,527.47. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 25,945 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $35.09, for a total transaction of $910,410.05. Following the completion of the transaction, the chief financial officer now owns 184,054 shares in the company, valued at $6,458,454.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 332,239 shares of company stock worth $11,824,710. 19.60% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its position in LeMaitre Vascular by 311.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 82,717 shares of the medical instruments supplier’s stock valued at $2,974,000 after buying an additional 62,623 shares in the last quarter. UBS Group AG boosted its position in LeMaitre Vascular by 40.3% in the fourth quarter. UBS Group AG now owns 19,271 shares of the medical instruments supplier’s stock valued at $693,000 after buying an additional 5,531 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its position in LeMaitre Vascular by 5.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 163,194 shares of the medical instruments supplier’s stock valued at $5,862,000 after buying an additional 8,305 shares in the last quarter. Capital Impact Advisors LLC boosted its position in LeMaitre Vascular by 5.6% in the fourth quarter. Capital Impact Advisors LLC now owns 62,055 shares of the medical instruments supplier’s stock valued at $2,231,000 after buying an additional 3,297 shares in the last quarter. Finally, Stifel Financial Corp acquired a new position in LeMaitre Vascular in the fourth quarter valued at about $222,000. Hedge funds and other institutional investors own 79.54% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Golden Cross

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.